# Henrik GrÃ¶nberg

List of Publications by Year
in descending order



Version: 2024-02-01

| | | | |
|---|---|---|---|
| 142 papers | 17,506 citations | 53794 45 h-index | 16183 124 g-index |
| 148 all docs | 148 docs citations | 148 times ranked | 27804 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. Nature Medicine, 2022, 28, 154-163. | 30.7 | 143 |
| 2 | Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study. European Urology, 2022, 82, 12-19. | 1.9 | 4 |
| 3 | Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761. | 3.9 | 14 |
| 4 | Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer. European Urology Focus, 2022, 8, 1617-1621. | 3.1 | 7 |
| 5 | A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study. European Urology Open Science, 2022, 38, 32-39. | 0.4 | 2 |
| 6 | Association of 5Î±-Reductase Inhibitors With Prostate Cancer Mortality. JAMA Oncology, 2022, 8, 1019. | 7.1 | 18 |
| 7 | Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks. Bioinformatics, 2022, 38, 3462-3469. | 4.1 | 9 |
| 8 | Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer. World Journal of Urology, 2021, 39, 1797-1804. | 2.2 | 10 |
| 9 | Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort. Prostate Cancer and Prostatic Diseases, 2021, 24, 120-127. | 3.9 | 5 |
| 10 | Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test. Prostate Cancer and Prostatic Diseases, 2021, 24, 457-464. | 3.9 | 1 |
| 11 | Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). Journal of the National Cancer Institute, 2021, 113, 632-640. | 6.3 | 9 |
| 12 | Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75. | 21.4 | 264 |
| 13 | Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 532-541. | 3.9 | 16 |
| 14 | Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications, 2021, 12, 1236. | 12.8 | 40 |
| 15 | The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects. European Urology Open Science, 2021, 24, 43-51. | 0.4 | 2 |
| 16 | Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. European Urology Open Science, 2021, 24, 11-16. | 0.4 | 2 |
| 17 | Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML. Blood Advances, 2021, 5, 1003-1016. | 5.2 | 12 |
| 18 | Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 1588. | 3.7 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | KLK3 SNPâ€“SNP interactions for prediction of prostate cancer aggressiveness. Scientific Reports, 2021, 11, 9264. | 3.3 | 5 |
| 20 | Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. European Urology Oncology, 2021, 4, 570-579. | 5.4 | 38 |
| 21 | MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. New England Journal of Medicine, 2021, 385, 908-920. | 27.0 | 184 |
| 22 | Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncology, The, 2021, 22, 1240-1249. | 10.7 | 83 |
| 23 | Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer. European Urology Oncology, 2020, 3, 640-647. | 5.4 | 15 |
| 24 | Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncology, The, 2020, 21, 222-232. | 10.7 | 364 |
| 25 | Identification and Validation of Leucine-rich Î±-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. European Urology Open Science, 2020, 21, 51-60. | 0.4 | 13 |
| 26 | Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. Journal of Clinical Pathology, 2020, 73, 630-635. | 2.0 | 9 |
| 27 | A Nordic initiative for a more personal and accurate diagnostic pathway for prostate cancer. Scandinavian Journal of Primary Health Care, 2020, 38, 249-250. | 1.5 | 2 |
| 28 | The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers, 2020, 12, 3254. | 3.7 | 16 |
| 29 | Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia. Blood Cancer Journal, 2020, 10, 67. | 6.2 | 6 |
| 30 | The effect of sample size on polygenic hazard models for prostate cancer. European Journal of Human Genetics, 2020, 28, 1467-1475. | 2.8 | 14 |
| 31 | A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1731-1738. | 2.5 | 27 |
| 32 | The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials, 2020, 21, 579. | 1.6 | 16 |
| 33 | Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50â€“69 years with PSA â‰¥3â€‰ng/ml. Scandinavian Journal of Urology, 2020, 54, 1-6. | 1.0 | 11 |
| 34 | The economic burden of prostate cancer â€“ a Swedish prevalence-based register study. BMC Health Services Research, 2020, 20, 448. | 2.2 | 19 |
| 35 | Has the PROPHECY of AR-V7 Been Fulfilled?. Journal of Clinical Oncology, 2019, 37, 2181-2182. | 1.6 | 7 |
| 36 | Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 2019, 76, 831-842. | 1.9 | 148 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431. | 12.8 | 88 |
| 38 | Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI. BMJ Open, 2019, 9, e027816. | 1.9 | 11 |
| 39 | Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study. PLoS ONE, 2019, 14, e0218280. | 2.5 | 7 |
| 40 | A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. European Urology Oncology, 2019, 2, 490-496. | 5.4 | 13 |
| 41 | Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2019, 5, 1060. | 7.1 | 17 |
| 42 | Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer. Prostate, 2019, 79, 920-928. | 2.3 | 9 |
| 43 | The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. BMJ Open, 2019, 9, e027958. | 1.9 | 15 |
| 44 | A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. PLoS ONE, 2019, 14, e0211918. | 2.5 | 10 |
| 45 | The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort. Prostate Cancer and Prostatic Diseases, 2019, 22, 137-142. | 3.9 | 20 |
| 46 | Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. International Journal of Cancer, 2019, 144, 1195-1204. | 5.1 | 31 |
| 47 | TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 1766-1773. | 7.0 | 117 |
| 48 | Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216. | 2.5 | 21 |
| 49 | Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik GrÃ¶nberg, Martin Eklund, Wolfgang Picker, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. Eur Urol 2018;74:722â€“8. European Urology, 2019, 75, e104-e105. | 1.9 | 0 |
| 50 | Response to Walsh. Journal of the National Cancer Institute, 2019, 111, 748-748. | 6.3 | 0 |
| 51 | Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study. European Urology Focus, 2019, 5, 842-848. | 3.1 | 4 |
| 52 | Development and Validation of a Novel RNA Sequencingâ€“Based Prognostic Score for Acute Myeloid Leukemia. Journal of the National Cancer Institute, 2018, 110, 1094-1101. | 6.3 | 15 |
| 53 | The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. European Urology, 2018, 74, 204-210. | 1.9 | 68 |
| 54 | Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 57-63. | 3.9 | 134 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. British Journal of Cancer, 2018, 118, 266-276. | 6.4 | 12 |
| 56 | Reply to Ola Bratt and Anna Ã–fverholm's Letter to the Editor re: Peter StrÃ¶m, Tobias NordstrÃ¶m, Henrik GrÃ¶nberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.12.028. European Urology, 2018, 74, e10-e11. | 1.9 | 0 |
| 57 | Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ: British Medical Journal, 2018, 360, j5757. | 2.3 | 153 |
| 58 | Risk of Prostate Cancer in Men Treated With 5Î±-Reductase Inhibitorsâ€"A Large Population-Based Prospective Study. Journal of the National Cancer Institute, 2018, 110, 1216-1221. | 6.3 | 27 |
| 59 | Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model. European Urology Focus, 2018, 4, 385-387. | 3.1 | 9 |
| 60 | The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50â€"69 yr Compared with Current Prostate Cancer Testing. European Urology Focus, 2018, 4, 707-710. | 3.1 | 42 |
| 61 | Summary statement on screening for prostate cancer in Europe. International Journal of Cancer, 2018, 142, 741-746. | 5.1 | 29 |
| 62 | Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine, 2018, 10, 85. | 8.2 | 94 |
| 63 | Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616. | 12.8 | 43 |
| 64 | Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology, 2018, 74, 722-728. | 1.9 | 70 |
| 65 | Predictors of participation in risk-based prostate cancer screening. PLoS ONE, 2018, 13, e0200409. | 2.5 | 12 |
| 66 | Re: Tobias NordstrÃ¶m, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik GrÃ¶nberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139â€"46. European Urology, 2018, 74, e35-e36. | 1.9 | 2 |
| 67 | Effects of pre-notification, invitation length, questionnaire length and reminder on participation rate: a quasi-randomised controlled trial. BMC Medical Research Methodology, 2018, 18, 3. | 3.1 | 27 |
| 68 | Expression levels of long non-coding RNAs are prognostic for AML outcome. Journal of Hematology and Oncology, 2018, 11, 52. | 17.0 | 43 |
| 69 | AA9int: SNP interaction pattern search using non-hierarchical additive model set. Bioinformatics, 2018, 34, 4141-4150. | 4.1 | 3 |
| 70 | Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936. | 21.4 | 652 |
| 71 | Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256. | 12.8 | 88 |
| 72 | SNP interaction pattern identifier (SIPI): an intensive search for SNPâ€"SNP interaction patterns. Bioinformatics, 2017, 33, 822-833. | 4.1 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. European Urology, 2017, 72, 192-200. | 1.9 | 106 |
| 74 | E-Science technologies in a workflow for personalized medicine using cancer screening as a case study. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 950-957. | 4.4 | 4 |
| 75 | Genetic profile of ductal adenocarcinoma of the prostate. Human Pathology, 2017, 69, 1-7. | 2.0 | 20 |
| 76 | Bioinformatoryâ€assisted analysis of nextâ€generation sequencing data for precision medicine in pancreatic cancer. Molecular Oncology, 2017, 11, 1413-1429. | 4.6 | 20 |
| 77 | Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. European Urology Focus, 2017, 3, 526-528. | 3.1 | 14 |
| 78 | Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer, 2017, 117, 734-743. | 6.4 | 7 |
| 79 | Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. International Journal of Cancer, 2017, 140, 322-328. | 5.1 | 17 |
| 80 | Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. European Urology, 2017, 72, 22-31. | 1.9 | 37 |
| 81 | Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 studyâ€"GrÃ¶nberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7. World Journal of Urology, 2017, 35, 895-896. | 2.2 | 0 |
| 82 | Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. Clinical Cancer Research, 2017, 23, 2584-2592. | 7.0 | 15 |
| 83 | Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. International Journal of Cancer, 2017, 140, 75-85. | 5.1 | 28 |
| 84 | Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy. BMC Urology, 2017, 17, 92. | 1.4 | 3 |
| 85 | Differential impact of RB status on E2F1 reprogramming in human cancer. Journal of Clinical Investigation, 2017, 128, 341-358. | 8.2 | 83 |
| 86 | Prevalence and heterogeneity of androgen receptor splice variants and intra-AR structural variation in patient with castration-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, 11530-11530. | 1.6 | 0 |
| 87 | The In Vitro Stability of Circulating Tumour DNA. PLoS ONE, 2016, 11, e0168153. | 2.5 | 18 |
| 88 | Body mass index in relation to serum prostateâ€specific antigen levels and prostate cancer risk. International Journal of Cancer, 2016, 139, 50-57. | 5.1 | 25 |
| 89 | PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811. | 3.2 | 174 |
| 90 | Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers. Scientific Reports, 2016, 6, 38037. | 3.3 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Total antioxidant intake and prostate cancer in the Cancer of the Prostate in Sweden (CAPS) study. A case control study. BMC Cancer, 2016, 16, 438. | 2.6 | 16 |
| 92 | Study design requirements for RNA sequencing-based breast cancer diagnostics. Scientific Reports, 2016, 6, 20200. | 3.3 | 2 |
| 93 | The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments. Nature Reviews Clinical Oncology, 2016, 13, 394-394. | 27.6 | 7 |
| 94 | Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Research, 2016, 76, 5103-5114. | 0.9 | 100 |
| 95 | Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. British Journal of Cancer, 2016, 115, 624-631. | 6.4 | 23 |
| 96 | Assessing the role of insulinâ€like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. International Journal of Cancer, 2016, 139, 1520-1533. | 5.1 | 26 |
| 97 | Telomere structure and maintenance gene variants and risk of five cancer types. International Journal of Cancer, 2016, 139, 2655-2670. | 5.1 | 43 |
| 98 | Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer Medicine, 2016, 5, 1125-1136. | 2.8 | 68 |
| 99 | Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions. Journal of the National Cancer Institute, 2016, 108, djw165. | 6.3 | 13 |
| 100 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067. | 9.4 | 157 |
| 101 | Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979. | 12.8 | 50 |
| 102 | Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Medicine, 2016, 14, 66. | 5.5 | 42 |
| 103 | Determining breast cancer histological grade from RNA-sequencing data. Breast Cancer Research, 2016, 18, 48. | 5.0 | 34 |
| 104 | Largeâ€scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. Molecular Oncology, 2016, 10, 825-837. | 4.6 | 20 |
| 105 | A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies. Scandinavian Journal of Urology, 2016, 50, 104-109. | 1.0 | 15 |
| 106 | Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nature Genetics, 2016, 48, 387-397. | 21.4 | 119 |
| 107 | The roles of stress and social support in prostate cancer mortality. Scandinavian Journal of Urology, 2016, 50, 47-55. | 1.0 | 16 |
| 108 | Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer. Acta OncolÃ³gica, 2016, 55, 45-51. | 1.8 | 39 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | The risk-based STHLM3 model to improve prostate cancer testing in men 50-69 years: Further health, economic, and clinic evaluation.. Journal of Clinical Oncology, 2016, 34, 36-36. | 1.6 | 0 |
| 110 | Association of changing prostate-specific antigen (PSA) levels on repeat testing with lower risk for Gleason Score (GS) â‰¥ 7 prostate cancer.. Journal of Clinical Oncology, 2016, 34, 284-284. | 1.6 | 0 |
| 111 | Polymorphisms In The Nitric-Oxide Synthase 2 Gene And Prostate Cancer Pathogenesis. Redox Biology, 2015, 5, 419. | 9.0 | 5 |
| 112 | Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474. | 2.3 | 54 |
| 113 | Body mass index and mortality in men with prostate cancer. Prostate, 2015, 75, 1129-1136. | 2.3 | 37 |
| 114 | The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. PLoS Genetics, 2015, 11, e1005378. | 3.5 | 331 |
| 115 | Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206. | 27.8 | 3,823 |
| 116 | A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery, 2015, 5, 368-379. | 9.4 | 56 |
| 117 | Tracking the Origin of Metastatic Prostate Cancer. European Urology, 2015, 67, 819-822. | 1.9 | 79 |
| 118 | The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. European Journal of Cancer, 2015, 51, 725-733. | 2.8 | 61 |
| 119 | Ovarian Cancer Risk After Salpingectomy: A Nationwide Population-Based Study. Journal of the National Cancer Institute, 2015, 107, dju410-dju410. | 6.3 | 300 |
| 120 | Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. European Urology, 2015, 68, 139-146. | 1.9 | 156 |
| 121 | Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. Human Molecular Genetics, 2015, 24, 5356-5366. | 2.9 | 128 |
| 122 | Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Human Molecular Genetics, 2015, 24, 5603-5618. | 2.9 | 50 |
| 123 | Two susceptibility loci identified for prostate cancer aggressiveness. Nature Communications, 2015, 6, 6889. | 12.8 | 88 |
| 124 | The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes and Control, 2015, 26, 1603-1616. | 1.8 | 77 |
| 125 | Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602. | 2.9 | 67 |
| 126 | Genome-Wide Association Study of Prostate Cancerâ€“Specific Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1796-1800. | 2.5 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | A differential protein solubility approach for the depletion of highly abundant proteins in plasma using ammonium sulfate. Analyst, The, 2015, 140, 8109-8117. | 3.5 | 20 |
| 128 | Prostate cancer screening in men aged 50â€“69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncology, The, 2015, 16, 1667-1676. | 10.7 | 308 |
| 129 | Physical Activity and Survival among Men Diagnosed with Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 57-64. | 2.5 | 115 |
| 130 | Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. PLoS Genetics, 2014, 10, e1004129. | 3.5 | 34 |
| 131 | A Genetic Score Can Identify Men at High Risk for Prostate Cancer Among Men With Prostate-Specific Antigen of 1â€“3 ng/ml. European Urology, 2014, 65, 1184-1190. | 1.9 | 32 |
| 132 | Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499. | 1.9 | 195 |
| 133 | A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109. | 21.4 | 408 |
| 134 | Defining the role of common variation in the genomic and biological architecture of adult human height. Nature Genetics, 2014, 46, 1173-1186. | 21.4 | 1,818 |
| 135 | Evaluation of Exome Sequencing to Estimate Tumor Burden in Plasma. PLoS ONE, 2014, 9, e104417. | 2.5 | 25 |
| 136 | Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391. | 21.4 | 492 |
| 137 | Mediterranean Diet Score and prostate cancer risk in a Swedish population-based caseâ€“control study. Journal of Nutritional Science, 2013, 2, e15. | 1.9 | 32 |
| 138 | Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010, 42, 937-948. | 21.4 | 2,634 |
| 139 | Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nature Genetics, 2008, 40, 281-283. | 21.4 | 357 |
| 140 | A common variant associated with prostate cancer in European and African populations. Nature Genetics, 2006, 38, 652-658. | 21.4 | 738 |
| 141 | Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta OncolÃ³gica, 2005, 44, 904-912. | 1.8 | 94 |
| 142 | DGGE screening of mutations in mismatch repair genes (hMSH2 and hMLH1) in 34 Swedish families with colorectal cancer. Clinical Genetics, 1998, 53, 131-135. | 2.0 | 19 |